Page last checked
Mitochondrial-derived peptide (research compound) · safety
No controlled human trial has published a side-effect rate or safety profile for MOTS-c. Here is what is actually known instead, and what that gap does and does not tell you.
MOTS-c is a peptide sixteen amino acids long. What makes it unusual is where it is coded: inside mitochondrial DNA, not in the cell nucleus that codes for nearly everything else. It is sold for fat loss, exercise capacity and metabolic aging, on the observation that blood levels fall as people get older.
The metabolic results are mouse experiments, injected into the abdomen. Levels do fall with age in people. But falling with age is not the same as helping when topped up, and nobody has tested the second thing. No trial has published a dose for a person.
No completed controlled human trial has shown which dose works for MOTS-c. There is no study-backed human dosing program to publish. Animal quantities are not converted into a human recommendation.
no human dose shown to work
Common reactions listed
None published
Serious reactions listed
None published
Boxed warning
No label exists
Strongest source
no human dose shown to work
Because no controlled human safety profile has been published for this compound, there is no evidence-based list of warning signs specific to it. That removes the early warning, not the risk. Any new, severe or lasting symptom belongs with a clinician. Tell them exactly what was taken.
There is no side-effect table on this page because there is no controlled human safety profile to build one from — and an empty table is more honest than a plausible one.
A published side-effect profile is not a summary of what people have noticed. It is the output of a specific process: a controlled trial enrolls a defined group and records every event, whether or not it looks related. It compares those rates against a control group, then publishes the result against a plan registered before the first dose. Where that process has not produced a profile, the output does not exist. Nothing stands in for it — not seller literature, not clinic protocols, not forum threads.
So the absence says something about the evidence, not about the compound. A profile nobody has measured is not a clean profile; it is an unmeasured one. Those two get confused constantly, and the confusion always runs in the direction that flatters the compound.
It is worth being blunt about the asymmetry. Rare and serious reactions are exactly the ones that scattered, self-reported experience is worst at catching. They are uncommon by definition, they can take time to appear, and they are easy to blame on something else.
The people who get them are also the least likely to come back and post an update. What shows up first in an unstudied compound is the mild and the immediate. That is a fact about how the reports get collected, not evidence about the compound.
The missing profile takes the rest of the scaffolding with it. With no approved label there is no list of who should avoid it, no documented interactions and no monitoring plan. There is no ceiling dose, and no channel carrying reports back to a regulator. Anyone taking an unapproved compound is outside all of those at once — and silence from a system that does not exist is not reassurance.
The absence here is total rather than partial. Some unstudied compounds at least have a handful of people who took them under supervision. This one has none: every human measurement ever published is of the peptide a body already makes for itself.
The human work on this molecule samples what circulates naturally and watches how the level tracks with age and fitness. That is observation. Nobody in any of it received a thing.
The step from one to the other is easy to skip and it is the whole distinction. A level that falls as people get older tells you the level falls. It does not tell you that topping it up helps, and it says nothing whatever about what happens to somebody who tries.
This peptide is genuinely novel. A cell reads it from inside mitochondrial DNA rather than from the nuclear genome, and that is why its description drew interest well beyond metabolism laboratories.
Novelty runs the other way on a safety page. Nobody has switched this pathway on in a person, so nobody has watched for the ways it might go wrong. The animal work that makes it interesting is precisely the work that cannot supply them.
FDA’s compounding committee examined the substance for obesity and osteoporosis. The agency then proposed against adding it to the list that would let pharmacies prepare it. No outcome document has appeared since.
A proposal is not a ban, and a review is certainly not an approval. What it settles is narrower and still worth having. The body whose job is to ask this question has asked it, and its answer so far is not a favorable one.
Four readings of an empty safety record go around. Each one turns a missing measurement into reassurance.
| The claim | What the evidence shows |
|---|---|
| Nothing serious has been reported. | Nothing has been systematically collected. A report needs a system that receives it, strips out duplicates and counts it. For an unapproved compound there is no such system, so silence is what you would get either way. |
| The studies look clean. | The published work is overwhelmingly in animals or too small and uncontrolled to produce a safety rate. Animal findings do not carry over to people at human doses over human timescales, and uncontrolled exposure supplies no comparison group or denominator. |
| People have used it for years. | Informal use is not monitoring. Years of unmeasured use produce familiarity and confidence. They do not produce a denominator, a comparison group, or a rate. |
| People seem to handle it well. | How well people handle a compound is measured against a control group. Without that comparison, the claim is only the writer’s impression. |
No human safety profile has been published for this compound. If that changes, the results should be reported with the study size, comparison group and citation—not filled in with assumptions.
No controlled human study has published a side-effect rate or safety profile. That describes the missing evidence, not the compound: unmeasured does not mean safe.
The published human evidence cannot answer that either way. Reliable safety estimates need systematic collection, a total number treated and a comparison group; none is available here.
Take the symptom to a clinician, and say exactly what was taken, how much and for how long. Clinicians assess symptoms without needing an approved label to exist, and leaving out the detail removes the one piece of context that changes what they look for.
The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.